An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer

NCT02743494 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

794

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Cancer

Interventions

DRUG: Nivolumab
OTHER: Placebo

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]